Bioaffinity Technologies, Stock Probability of Future Stock Price Finishing Over 2.61
| BIAF Stock | USD 1.20 0.02 1.64% |
BioAffinity |
BioAffinity Technologies, Target Price Odds to finish over 2.61
The tendency of BioAffinity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 2.61 or more in 90 days |
| 1.20 | 90 days | 2.61 | near 1 |
Based on a normal probability distribution, the odds of BioAffinity Technologies, to move over $ 2.61 or more in 90 days from now is near 1 (This bioAffinity Technologies, probability density function shows the probability of BioAffinity Stock to fall within a particular range of prices over 90 days) . Probability of bioAffinity Technologies, price to stay between its current price of $ 1.20 and $ 2.61 at the end of the 90-day period is about 92.1 .
Given the investment horizon of 90 days BioAffinity Technologies, has a beta of 0.85 suggesting bioAffinity Technologies, market returns are reactive to returns on the market. As the market goes up or down, BioAffinity Technologies, is expected to follow. Additionally BioAffinity Technologies, has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. BioAffinity Technologies, Price Density |
| Price |
Predictive Modules for BioAffinity Technologies,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as bioAffinity Technologies,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioAffinity Technologies, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioAffinity Technologies, is not an exception. The market had few large corrections towards the BioAffinity Technologies,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold bioAffinity Technologies,, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioAffinity Technologies, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.39 | |
β | Beta against Dow Jones | 0.85 | |
σ | Overall volatility | 0.29 | |
Ir | Information ratio | -0.06 |
BioAffinity Technologies, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioAffinity Technologies, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for bioAffinity Technologies, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioAffinity Technologies, generated a negative expected return over the last 90 days | |
| BioAffinity Technologies, has high historical volatility and very poor performance | |
| BioAffinity Technologies, may become a speculative penny stock | |
| BioAffinity Technologies, has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies, currently holds 1.58 M in liabilities. bioAffinity Technologies, has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies,'s use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies, currently holds about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: bioAffinity Technologies stock hits 52-week low at 1.21 - Investing.com |
BioAffinity Technologies, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioAffinity Stock often depends not only on the future outlook of the current and potential BioAffinity Technologies,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioAffinity Technologies,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.7 M | |
| Cash And Short Term Investments | 2.8 M |
BioAffinity Technologies, Technical Analysis
BioAffinity Technologies,'s future price can be derived by breaking down and analyzing its technical indicators over time. BioAffinity Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of bioAffinity Technologies,. In general, you should focus on analyzing BioAffinity Stock price patterns and their correlations with different microeconomic environments and drivers.
BioAffinity Technologies, Predictive Forecast Models
BioAffinity Technologies,'s time-series forecasting models is one of many BioAffinity Technologies,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary BioAffinity Technologies,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about bioAffinity Technologies,
Checking the ongoing alerts about BioAffinity Technologies, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for bioAffinity Technologies, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| BioAffinity Technologies, generated a negative expected return over the last 90 days | |
| BioAffinity Technologies, has high historical volatility and very poor performance | |
| BioAffinity Technologies, may become a speculative penny stock | |
| BioAffinity Technologies, has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies, currently holds 1.58 M in liabilities. bioAffinity Technologies, has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies,'s use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies, currently holds about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: bioAffinity Technologies stock hits 52-week low at 1.21 - Investing.com |
Check out BioAffinity Technologies, Backtesting, BioAffinity Technologies, Valuation, BioAffinity Technologies, Correlation, BioAffinity Technologies, Hype Analysis, BioAffinity Technologies, Volatility, BioAffinity Technologies, History as well as BioAffinity Technologies, Performance. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.